This test is designed to detect carriers of Duchenne and Becker muscular dystrophy. Duchene muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders characterized by progressive muscle weakness and atrophy affecting skeletal muscles and the heart. DMD usually presents in males before the age of 5 and symptoms include difficulty running, climbing, and getting up from the floor.

This test is designed to detect carriers of Duchenne and Becker muscular dystrophy. Duchene muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders characterized by progressive muscle weakness and atrophy affecting skeletal muscles and the heart. DMD usually presents in males before the age of 5 and symptoms include difficulty running, climbing, and getting up from the floor. DMD progresses rapidly with wheelchair dependency by the age of 12 and death due to respiratory complications or dilated cardiomyopathy typically before the age of 30. BMD is a less severe disorder with later onset and slower progression. Males with BMD remain ambulatory beyond the age of 16 and typically live into their 40s with dilated cardiomyopathy the most common cause of death. Some males show little or no evidence of skeletal muscle disease but present with dilated cardiomyopathy, usually in their 20s to 40s. Targeted therapies may be available for some affected individuals and will likely improve the clinical course of these disorders. DMD (MIM 310200), BMD (MIM 300376), and DMD-associated dilated cardiomyopathy (MIM 302045) are caused by pathogenic variants in the DMD gene (NM_004006). The most common pathogenic variants in DMD are large deletions and duplications encompassing one or more exons of the gene. Females with a heterozygous pathogenic variant in DMD are carriers for a DMD-associated disorder. Male children of a female carrier have a 50% chance of being affected with the disorder. Female children of a female carrier have a 50% chance of being a carrier of the disorder. Additionally, females with a heterozygous pathogenic DMD variant may develop symptoms of these disorders, including muscle weakness and dilated cardiomyopathy. Pathogenic variants in DMD have a high incidence of de novo occurrence and germline mosaicism; therefore, individuals with a negative carrier screen may still be at risk for having a child with a DMD-associated disorder. This test is intended for pre/post-conception carrier screening and is not intended for diagnostic testing.

Gene(s)

DMD

MIM

310200 300376 3020045

Methodology

Billing

CPT Code(s)
81408 x 1

Ordering

Test Code
6003

Additional Test Codes
Please call for pricing

Turnaround Time
Typically within 2 weeks from receipt of a sample in the laboratory.

Specimens
Whole blood: purple-top (EDTA) tube, minimum of 3 ml
Genomic DNA: minimum of 3 µg (at a concentration of at least 30 ng/µl)

Shipping
Ship all specimen types at room temperature by overnight courier. Do not freeze.

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

News

October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More